CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570) Eye Health (703)
KalVista Pharmaceuticals (NASDAQ: KALV) is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need. The company has develope...Show all
Company (IPO / Went public)
Phone: 857-999-0075
55 Cambridge Parkway
Suite 901E
Cambridge, 02142
Massachusetts, United States
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | Nov 26, 2015 | Sep 22, 2020 | Patent |
| Polymorphs of n-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors | Jun 01, 2017 | Aug 25, 2020 | Patent |
| N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | Jul 02, 2019 | Apr 07, 2020 | Patent |
| Pharmaceutical compositions | Sep 26, 2017 | Nov 19, 2019 | Patent |
| N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | Nov 26, 2015 | Jul 30, 2019 | Patent |
